Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients-Reference-Cited by-同舟云学术

Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients

Published:2018-10-16 Issue:2 Volume:79 Page:234-242
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Sekino Yohei¹²,Oue Naohide¹^ORCID,Mukai Shoichiro³,Shigematsu Yoshinori¹²,Goto Keisuke²⁴,Sakamoto Naoya¹,Sentani Kazuhiro¹,Hayashi Tetsutaro²,Teishima Jun²,Matsubara Akio²,Yasui Wataru¹

Affiliation:

1. Department of Molecular PathologyGraduate School of Biomedical and Health Sciences, Hiroshima UniversityMinami‐kuHiroshimaJapan

2. Department of UrologyGraduate School of Biomedical and Health Sciences, Hiroshima UniversityMinami‐kuHiroshimaJapan

3. Department of Gastroenterological and Transplant SurgeryApplied Life Sciences, Graduate School of Biomedical and Health SciencesMinami‐kuHiroshimaJapan

4. Cancer Biology ProgramUniversity of Hawaii Cancer CenterHonoluluHawaii

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23728

Reference35 articles.

1. The Epigenetic promise for prostate cancer diagnosis

2. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer